Better diagnosis of cardiac amyloidosis using warning signs
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This trial aims to better diagnose cardiac amyloidosis — a condition where abnormal proteins build up in the heart — by testing whether certain warning signs (called 'red flags') can help identify it. If you have any of these signs, the study will use heart scans to confirm the diagnosis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have at least one 'red flag' sign that might be linked to cardiac amyloidosis.
- You must be willing to participate in additional heart imaging tests (like an MRI or bone scan).
- You cannot have any metal implants (unless they are MRI-safe), severe claustrophobia, or severe kidney problems that would make the imaging tests unsafe.
- You must not have been diagnosed with another condition that causes abnormal substances to build up in your heart.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses two types of imaging (PET/CT and MRI) to see if they can better predict outcomes for people with AL cardiac amyloidosis. The goal is to improve how doctors understand and manage the disease.
This study tests if a pacemaker or defibrillator can spot a rare heart condition called cardiac amyloidosis by measuring electrical signals in the right ventricle. It might help people with thickened heart walls find out sooner if they have this treatable disease.
This study tests a new type of imaging scan ([64Cu]FBP8 PET) to detect blood clots that may form in the heart's left atrial appendage (a small pouch in the heart) in patients with amyloid cardiomyopathy (a disease where abnormal protein builds up in heart muscle) who also have irregular heartbeat. The scan may help doctors catch clots earlier and prevent strokes.
This study uses advanced heart scans and AI technology to find early signs of amyloidosis (a protein buildup in the heart) in people with atrial fibrillation. Catching it early may help prevent serious heart problems.
This study looks at how a type of heart condition called transthyretin cardiac amyloidosis changes over time, using a special imaging test called a bone scan. The goal is to see if the scan can help track the disease and potentially improve care.
This study measures how well the heart’s tiny blood vessels work in people with cardiac amyloidosis, using special heart testing. It may help doctors understand the disease better and improve how patients are evaluated over time.
Hear when a new Cardiac Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.